



Published on *British Columbia Drug and Poison Information Centre (BC DPIC)* (<http://www.dpic.org>)

[Home](#) > [Drug Product Listings](#) > [Darunavir](#) > [Printer-friendly PDF](#)

Darunavir

Synonym(s):

TCM-114

Trade Name:

Prezista

Manufacturer/Distributor:

Tibotec (a division of Janssen-Ortho)

1-800-567-3331 (Medical Information)

www.janssen-ortho.com

Classification:

Antiviral agent

ATC Class:

J05AE10 - protease inhibitor

Status:

active

Notice of Compliance (yyyy/mm/dd):

NOC with conditions 2006/07/28; 2009/02/11 Fulfillment of commitment

Date Marketed in Canada (yyyy/mm/dd):

2006

Presentation:

Tablet: 300 mg, DIN 02284057

Tablet: 400 mg, DIN 02324016

Tablet: 600 mg, DIN 02324024

Comments:

2006: Antiretroviral agent for the treatment of HIV. Darunavir is co-administered with ritonavir and other antiretroviral agents, and is indicated for the treatment of HIV infection in adult patients who have failed prior antiretroviral therapy. 2009: can now be used in treatment-naïve patients.

Keywords: darunavir

protease inhibitors

antiviral agents

aids

Access:

public

We are grateful to all the First Nations who have cared for and nurtured the lands and waters around us for all time, including the xʷmʷkʷyʷm (Musqueam), Skʷwxʷuʷmesh

U?xwumixw (Squamish Nation), and s?l?ilw?ta? (Tsleil-Waututh Nation) on whose unceded and ancestral territory our centre is located.

© 2024 BC Drug and Poison Information Centre

All material found on the BC Drug and Poison Information Centre (DPIC) website is provided for informational purposes only. It is *not* meant to replace the expert advice of a healthcare professional such as a physician, pharmacist, nurse or qualified poison specialist. Use of this site is governed and restricted by specific terms of use. Please review the **full terms and conditions** below prior to using the DPIC website. In the event of a poisoning emergency, call your local poison control centre immediately. Portions of this web site are intended for healthcare professionals. Interpretation and application of information may require more detailed explanation than contained herein, particularly regarding any clinical information that is found in or linked to this site. Patients are advised to consult their health care provider regarding diagnosis and treatment, and for assistance in interpreting these materials and applying them in individual cases.

Terms and Conditions

Source URL (retrieved on 2025-07-30 13:45): <http://www.dpic.org/druglisting/darunavir>